Medicine and Dentistry
Patient
100%
Nivolumab
27%
Adverse Event
16%
Classical Hodgkin Lymphoma
16%
Brentuximab Vedotin
16%
Overall Survival
11%
Spontaneous Remission
11%
Progression Free Survival
11%
Immunosuppressive Drug
5%
Survival Rate
5%
Follow up
5%
Pimeprofen
5%
Exanthem
5%
Blocking Antibody
5%
Fever
5%
Microenvironment
5%
Hypothyroidism
5%
Pruritus
5%
Treatment Duration
5%
Programmed Death 1 Ligand 1
5%
Therapeutic Procedure
5%
Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Nivolumab
27%
Adverse Event
16%
Brentuximab Vedotin
16%
Classical Hodgkin Lymphoma
16%
Overall Survival
11%
Progression Free Survival
11%
Remission
11%
Death
11%
Immunosuppressive Agent
5%
Blocking Antibody
5%
Survival Rate
5%
Pimeprofen
5%
Rash
5%
Hypothyroidism
5%
Fever
5%
Pruritus
5%
Programmed Death 1 Ligand 1
5%
Immunology and Microbiology
Nivolumab
27%
Brentuximab Vedotin
16%
Overall Survival
11%
Progression Free Survival
11%
Immunosuppressive Drug
5%
Survival Rate
5%
Blocking Antibody
5%
Programmed Death 1 Ligand 1
5%
Time
5%
Neuroscience
Nivolumab
27%
Lymphoma
16%
Brentuximab Vedotin
16%
Blocking Antibody
5%
Hypothyroidism
5%
Programmed Death 1 Ligand 1
5%
Nursing and Health Professions
Classical Hodgkin Lymphoma
16%
Brentuximab Vedotin
16%